Navigation Links
SuperGen in Medical News

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

... DUBLIN, Calif., March 2 /PRNewswire-FirstCall/ -- supergen Inc., (Nasdaq: SUPG ), a pharmaceutical company ..., representing approximately 1.5 million shares of supergen common stock. December 2008: The...employees. Conference Call Information supergen will host a conference call to discuss the results...

SuperGen to Announce 2008 Fourth Quarter and Fiscal Year-End Financial Results March 2, 2009

...eplay and conference call replay will be available for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Present at BIO CEO & Investor Conference on February 10, 2009

...t www.supergen.com . The webcast will be archived for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008

...armaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For mo...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...aq: OREX ) Repros Therapeutics Inc. (Nasdaq: RPRX ) Sangamo BioSciences Inc. (Nasdaq: SGMO ) Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ) supergen Inc. (Nasdaq: SUPG ) Transition Therapeutics Inc. (Nasdaq: TTHI ) XOMA Ltd. (Nasdaq: XOMA ) Neuroscience Index (HHN) Drop Neurochem Inc. (...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

... DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... be a key player in this resistance. Scientists at supergen found that MP470 inhibits these kinases and data p...ignificant unmet clinical need in oncology. About supergen Based in Dublin, Calif.,...

SuperGen Reports 2007 Third Quarter Financial Results

... DUBLIN, Calif., Oct. 29 /PRNewswire-FirstCall/ -- supergen Inc., (Nasdaq: SUPG ), a pharmaceutical company d...itioned to David S. Smith, Ph.D., who joined supergen in March 2007 as Vice President, Regulatory and ...Consumer Healthcare. Conference Call Information supergen will host a conference call to discuss the results...

SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007

... DUBLIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...ference call will be available for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a phar...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference

... DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... malignancies About supergen Based in Dublin, Calif., SuperGen, Inc. is a phar...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...
SuperGen in Medical Technology

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... DUBLIN, Calif., Dec. 8 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company d...f Pennsylvania support this hypothesis." supergen recently received clearance for a phase I trial wi...ell as several types of leukemias. About supergen Based in Dublin, Calif., SuperGen, Inc. is a ...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG), a pharmaceutical company dedi...n was developed through a pivotal Phase 3 study by supergen and partnered to MGI PHARMA, INC. (acquired by Eis...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

... DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...ner, Manager of Discovery Biology, highlighted how supergen scientists used the company's CLIMB(TM) technology...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

... DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

Data Show SuperGen's MP-470 is Safe in Humans

... DUBLIN, Calif., April 15 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

...DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de....com . About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

...g erlotinib resistance DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

... DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...mation, future events or otherwise. Contacts: supergen Timothy L. Enns S.V.P., Corporate Communications...evelopment (925) 560-0100 tenns@supergen.com supergen Mary M. Vegh Manager, Investor Relations (925) ...
SuperGen in Biological Technology

Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer

Dr. David S. Smith to Head Regulatory and Quality Affairs DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malign...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

..., representing approximately 1.5 million shares of supergen common stock. supergen will initiate a Phase I clinical trial to evaluate...as several types of human leukemias. About supergen Based in Dublin, Calif., SuperGen, Inc. is...

SuperGen Reports 2008 Third Quarter Financial Results

...act 571: Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a small molecule JAK2 inhibitor. Conference Call Information supergen will host a conference call to discuss the 2008 third quarter financial results today at 1:30 p.m. PT / 4:30 p.m. ET. The webcast will be accessible v...

SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008

... DUBLIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery ... will be available for 90 days. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the discovery and development...

SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy

... drug designation for GBM, an often fatal form of brain cancer, can entitle supergen to seven years of market exclusivity. SuperGen's lead product candidate has...e spectrum of cancers, including non-small cell lung cancer. Furthermore, supergen presented four additional posters at the Symposium that reviewed clinical a...

SuperGen Reports 2008 Second Quarter Financial Results

...nager of Discovery Biology, highlighted how supergen scientists used the Company's CLIMB technology to ... scientific forum. Conference Call Information supergen will host a conference call to discuss the results...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008

...armaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For mo...

SuperGen Reports 2008 First Quarter Financial Results

...DUBLIN, Calif., April 28 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ) today reported financial res...red to decitabine. Conference Call Information supergen will host a conference call to discuss the results...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008

...DUBLIN, Calif., April 22 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...event. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008

...DUBLIN, Calif., April 21 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... days. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...
Other Tags
(Date:4/21/2015)... 2015 As a provider of holistic, ... that their rehabilitation strategy, which involves various treatment modalities, ... In an effort to offer hope and encouragement to ... lives, Best Drug Rehabilitation has featured a series of ... successful graduates of their recovery program. , One ...
(Date:4/21/2015)... Zane Benefits, the leader in individual ... publication of a new guide “Health Reimbursement Accounts in ... the health insurance industry, including how employers can use ... what is permitted when implementing an HRA. This simple, ... which HRAs are compliant this year. , According ...
(Date:4/21/2015)... April 21, 2015 Zane Benefits, a ... today its CEO Rick Lindquist has been selected as ... , According to Rick Lindquist, “There is a massive ... Zane Benefits’ small business solutions are at its forefront. ... by Employee Benefit Adviser’s Rising Stars.” , According to ...
(Date:4/21/2015)... 21, 2015 Optimity Advisors ( ... advisory firm that helps clients in complex industries ... that the Association of Community Affiliated Plans ... ACAP represents 58 local, not-for-profit, community-affiliated Safety Net ... million people primarily enrolled in public or state-sponsored ...
(Date:4/21/2015)... When a bandage sticks to an injury site ... solve this problem two inventors from Festus, Mo., designed ... helps a cut, burn, abrasion or wound heal more ... The bandage is easy to use, versatile and producible ... to the St. Louis office of InventHelp. It is ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Graduate Discusses Making Amends and Rebuilding Relationships 2Health News:Zane Benefits’ CEO Named Top 20 Rising Stars 2Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
Breaking Biology News(10 mins):Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
Other Contents